Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Novel biomarkers for diagnostics and drug R&D: What is industry looking for?

Tom Metcalfe of F. Hoffmann-La Roche AG talks about what the pharmaceutical industry is looking for in novel biomarkers for diagnostics and drug research and development.

Part of Dx2010, a workshop at MaRS focused on best practices and regulatory considerations for developing gene-based diagnostic and prognostic tests.

  • Login to see the comments

Novel biomarkers for diagnostics and drug R&D: What is industry looking for?

  1. 1. Novel Biomarkers for Diagnostics and Drug R&D – What is industry looking for? Tom Metcalfe, F. Hoffmann-La Roche AG Ontario Genomics Institute, Markers to Markets Workshop, Toronto, June 22nd, 2010
  2. 2. "#$%&'#()* +,)-%./0)/0-.1-0,#$-2*)$)/0'0#./-*)2*)$)/0$-0,)- 2)*$./'&-.2#/#./$-.1-0,)-2*)$)/0)*-'/3-/.0- /)%)$$'*#&4-0,.$)-.1-5.%,) !
  3. 3. +,)-2)*$2)%0#7)-.1-0,)-8,'*('%)90#%'&$-:9$#/)$$ 6
  4. 4. A"B)C(1D"(+)50)8&#/<")1/)%&")*&#(7#)E/?,+%(B !"#$%&'#(")*("++,("+- 6'5/571')*("++,("+- 9":);"'&/5$5<1"+- ."/"01%231+4)3#%15 85+%2."/"01%)3#%15 6=>#/?"?)8#>#@1$1%1"+ ;
  5. 5. A"B)C(1D"(+)50)8&#/<")1/)F,()E/?,+%(B A call for more effective and safer drugs 6001'#'B J#0"%B I/#$<"+1'+ C(,<)3"+>5/+")3#%"G)H L>M IB >'/.1# '7)/0#$ JB K.7'*0#$ ;B 8#/'"( :'4)* !B K.7'*0#$ B =->2)'*$-)0-'&?@-+*)/3$-A.&-A)3@-!BB=C-!-D'E'*.9 )0-'&?@-FGAG@-=HHI <
  6. 6. A"B)C(1D"(+)50)8&#/<")1/)F,()E/?,+%(B Economic pressures intensify focus on improved benefit-cost ratio R?>?-Q)'&0,%'*)->2)/3#/S@-R>T-:#&&#./$- R?>?-Q)'&0,%'*)->2)/3-'$-U-.1-L"8 OMMM NMH NLMM KP KOH H KLMM !BBB !BBI !B=< !BBB !BBI !B=< >.9*%)N-O)/0)*$-1.*-A)3#%'*)-'/3-A)3#%'#3@-P11#%)-.1-0,)-G%09'*4@-K'0#./'&-Q)'&0,->0'0#$0#%$-L*.92 J
  7. 7. A"B)C(1D"(+)50)8&#/<")1/)F,()E/?,+%(B) Step-change needed in Pharma R&D LX 9":)R5$"',$#()6/%1%1"+)S9R6T U)OV)./) NO NK U)KV)./) KW) KWWP) NMMV MY MW 3QC)J>"/? >.9*%)$N-W"GXO"Y5 "'0'@-8,5AG 3'0'@-8*#%)-Z'0)*,.9$)-O..2)*$-'/'&4$#$@-8,'*('-!B!B V
  8. 8. 6D5$,%15/)50)R"?1'1/")[)[)[)#/?)*!8 Progress in therapy driven by new technologies 6D5$,%15/)50)R"?1'1/" Z,%,(" ! ;5?#B JB+%"7+).15$5<B R5$"',$#( E77,/5$5<B R"?1'1/" F/'5$5<B KWVM ;(#/+>$#/%#%15/ R5?"(/ 8(1%1'#$)8#(" R"?1'1/" R1'(5@15$5<B ^#''1/#%15/ 6#($B KYLM J,(<"(B R"?1'1/" .$""?1/< KNMM I/%1_," R"?1'1/" ! 6D5$,%15/)50) ;5,'&G)J7"$$) C1++"'%15/ R1'(52 2(#B R"%#@5$1%" 2571'+ .152 ;"'&/5$5<1"+ Q);#+%" +'5>" I/#$B]"(+ S1["[)*83T 1/05(7#%1'+ I
  9. 9. A"B)C(1D"(+)50)8&#/<");5:#(?+)*"(+5/#$1+"? !"#$%&'#(")S*!8T PHC is key to enabling highly differentiated medicines !"#$%&'#(")*("++,("+- 6'5/571')*("++,("+- 9":);"'&/5$5<1"+- ."/"01%231+4)3#%15 ."/"01%285+%)3#%15 6=>#/?"?)8#>#@1$1%1"+ 9""?)05()&1<&$B)?100"("/%1#%"?)7"?1'1/"+ %&#%)>5+1%1D"$B)17>#'%)>,@$1')&"#$%& J5'1"%B)#/?)>#B5(+ :1$$)(":#(?)+1</101'#/%)1//5D#%15/ H
  10. 10. `&#%)1+)*"(+5/#$1+"?)!"#$%&'#("a Encompasses many actions to improve patient outcomes .(5#?"+%)+"/+" [ P20#('&-'3'20'0#./-.1-,)'&0,%'*)-3)%#$#./$-QO-('#/0)/'/%)@-(./#0.*#/S@- 2*)7)/0'0#7)-'/3-0,)*'2)90#%-$0)2$]-^'$)3-./-'-2)*$./_$-#/3#7#39'&- %,'*'%0)*#$0#%$@-,)'&0,%'*)-$0'09$-'/3-2)*$./'&-$#09'0#./? [ `/%&93)$-0,)-9$)-.1-3#'S/.$0#%$@-%,.#%)-.1-0,)*'24@-%,.#%)-.1-3.$)@-0#(#/S-'/3- 1*)a9)/%4-.1-3.$) Z5()'57>#/1"+)1/)%&")>&#(7#b@15%"'&)1/?,+%(B):5(4+>#'" [ 8,'*('-'/3-:#.0)%,@-#/-0,)#*-%'2'%#04-'$-#/39$0*4-()(^)*$-b,#%,-3#$%.7)*@- 3)7)&.2-'/3-('*c)0-#//.7'0#7)-()3#%#/)$-'*)-$0*./S&4-2.$#0#./)3-0.-#(2'%0-'- %*#0#%'&-2'*0-.1-8)*$./'&#$)3-Q)'&0,%'*) [ Y/$9*)-0,'0-b)-3)7)&.2-.9*-()3#%#/)$-#/-'-b'4-0,'0-b)-9/3)*$0'/3 b,#%,- S*.92$-.1-2'0#)/0$-3)*#7)-0,)-(.$0-/)0-^)/)1#0-)11#%'%4-'/3-$'1)04]-1*.(-0,)- /.7)&-()3#%#/)$-0,'0-b)-3)7)&.2 =B
  11. 11. *"(+5/#$1+"? !"#$%&'#(")#/?)C(,< C1+'5D"(B)#/?)C"D"$5>7"/% !"#$%&'()#'#*+,-.$/+-,*0$&1$+"#$0-23$0#4#)&('#*+$(-&%#// C"%"(71/1/<) C"D"$5>1/<) :&1'&)<(5,>+)50) 1//5D#%1D") >#%1"/%+)?"(1D") 7"?1'1/"+ 75+%)@"/"01%)0(57) %&")/":)7"?1'1/" ==
  12. 12. J57")50)%&")>(571+"+)50)*"(+5/#$1+"? !"#$%&'#(" Can we deliver on all of them? [ `//.7'0#7)-()3#%#/)$-b,#%,-'*)-^)00)*-0'*S)0)3-0.-0,.$)-(.$0-&#c)&4- 0.-*)$2./3-'/3-'*)-$'1)*-'/3-(.*)-)11#%'%#.9$-0,'/-%9**)/0- ()3#%#/)$-! [ G/-#/%*)'$)3-9/3)*$0'/3#/S-.1-,9('/-2'0,.2,4$#.&.S4 '/3-0,)- (.&)%9&'*-^'$#$-.1-3#$)'$)-! [ `(2*.7)3-2'0#)/0-3#'S/.$)$-! [ `(2*.7)3-2'0#)/0-%'*)-! [ A.*)-)11#%#)/0-9$)-.1-,)'&0,%'*)-*)$.9*%)$-! d [ >,.*0)*-'/3-&)$$-)e2)/$#7)-%&#/#%'&-0*#'&$d =!
  13. 13. J57")50)%&")75+%)7#c5()'&#$$"/<"+)50)?"$1D"(1/<) *"(+5/#$1+"? !"#$%&'#("dd [ `(2*.7)3-9/3)*$0'/3#/S-.1-,9('/-2'0,.2,4$#.&.S4 '/3-0,)-(.&)%9&'*-^'$#$-.1-3#$)'$)-#$-'- !"#$%&%" '%#()*+,)#"#)1.*-('c#/S-2*.S*)$$-#/-8QO [ 8'0#)/0$-/))3-0.-^)-%&.$)&4-#/7.&7)3-f b#0,.90-2'0#)/0$-%./$)/0#/S-0.-^)-#/7.&7)3-#/-%&#/#%'&- *)$)'*%,-2*.S*'($-'/3-3./'0#/S-^#.&.S#%'&-$'(2&)$-f ^&..3@-09(.9*-0#$$9)-)0%?-(9%,-.1- 0,)-b.*c-#$-/.0-2.$$#^&) [ :.0,-8,'*('-'/3-"#'S/.$0#%$-#/39$0*4-()(^)*$-(9$0-('c)-'-/9(^)*-.1-%.(2&)e- .*S'/#E'0#./'&-'/3-&.S#$0#%'&-'3'20'0#./$ [ `//.7'0#7)-*)S9&'0.*4-'22*.'%,)$-'*)-*)a9#*)3-O*#0#%'&-8'0,-`/#0#'0#7)-)0%?] [ Ye0)/$#7)-OAY-2*.S*'($-b#&&-^)-*)a9#*)3-#1-2,4$#%#'/$-'*)-0.-('c)-0,)-(.$0-.90-.1-8QO [ `(2*.7)3-3)%#$#./-$922.*0-$4$0)($-1.*-2,4$#%#'/$-'/3-.0,)*$ [ >#S/#1#%'/0-#//.7'0#./-#/-0,)-"#'S/.$0#%$-('*c)02&'%)-f ^.0,-1*.(-`g"--'/3-#('S#/S- )a9#2()/0-$922&#)*$-'/3-1*.(-%&#/#%'&-&'^$-' =6
  14. 14. 8&,%"+)#/?)e#??"(+)5/)%&")8(1%1'#$)*#%&-)857>#(#%1D") 600"'%1D"/"++G)*(5?,'%)^#$,"G)#/?)%&")f+")50).157#(4"(+)1/) C(,<)C"D"$5>7"/% [ +,)-#(2)*'0#7)-0.-2*.39%)-,#S,h7'&9)@-#//.7'0#7)-3*9S$-b#&&-#/0)/$#14@- %*)'0#/S-'-,#S,)*-2)*1.*('/%)-,9*3&)-1.*-/)b-0,)*'2)90#%$?-:'$#% ^#.()3#%'&-$%#)/%)-b#&&-!-+.#)"+&)!,#$%$,&()/%"0,.1(.' b#0,- 0'/0'&#E#/S-2.0)/0#'&-0.-#(2*.7)-7'&9)@-b,)*)'$-()0,.3$-0.-9$)-0,)(- )11)%0#7)&4-#/-$.+2)$(3(4"50(#&)6%44)(3"43()0".()'4"647?-+,)-^'&'/%)- ^)0b))/-0,)$)-1.*%)$-('4-b)&&-3)0)*(#/)-0,)-$9%%)$$-.*-1'#&9*)-.1- 0,)-3*9S-3)7)&.2()/0-)/0)*2*#$)-.7)*-0,)-/)e0-3)%'3)? F?-Z..3%.%c@-O&#/?-8,'*(?-'/3-+,)*?-!BBH]C-IJ@-=@-=!f=;? =;
  15. 15. 857>5/"/%+)50)*!8 Key steps to bringing new value to the practice of medicine " R/3)*$0'/3-,)0)*.S)/)#04-.1-3#$)'$)$ # "#$%.7)*-'/3-3)7)&.2-.(4(3,#&)/%"0,.1(.' $ >0*'0#14-2'0#)/0$-b#0,-3#'S/.$0#%-0)$0$ % :9#&3-)7#3)/%)-1.*-^)00)*-^)/)1#0h*#$c-*'0#. =<
  16. 16. *!8)1+)#%)%&")'5(")50)35'&"g+)/":)#>>(5#'&)%5)C(,<) C1+'5D"(B)#/?)C"D"$5>7"/% 3"+"#('& C"D"$5> 8577"('1#$1]" D)'3- A'*c)0 +'*S)0 L)/)*'0#./X- 8,'$)-B 8,'$)-` 8,'$)-`` 8,'$)-``` W#&#/S >)&)%0#./ P20#(#E'0#./ 8,'$)-`g "#$%.7)*4 Ye2&.*'0.*4-8,'$) 8.O O./1#*('0.*4-8,'$) 8,'$) ! ! ! ! ! :#.('*c)* O.(2'/#./-3#'S/.$0#% "e-&'9/%,X-8.$0h&'9/%,- )e2&.*'0#./ 1)'$#^#&#04-i-'00*'%0#7)/)$$ '$$)$$()/0 +'#&.*)3-2*)$%*#^#/S +'*S)0-#3)/0#1#%'0#./ 8'0#)/0-$)&)%0#./ i-(./#0.*#/S 3"+"#('&)#++#B ;"'&/1'#$$B)D#$1?#%"?)#++#B 8$1/1'#$$B)D#$1?#%"?)E^C)#++#B =J
  17. 17. C(,<)?"D"$5>7"/%)#/?)'57>#/15/)?1#</5+%1') ?"D"$5>7"/%)#(")50%"/)/5%)#$1</"? *&#(7#)3QC)>(5'"++) 8$1/1'#$) Q)?"'1+15/)>51/%+ 8#/?1?#%") 6/%(B)E/%5) J"$"'%15/ !,7#/ Z1$1/< C1+'5D"(B 6=>$5(#%5(B))))))))))))))))))))) 85/01(7#%5(B))))))))))))))))))))))) *&#+" *&#+" *58 *&#+" .157#(4"()C1+'5D"(B) .157#(4"()8#/?1?#%"+)))))))))))))))) .157#(4"()8#/?1?#%"+)C1+'5D"(BN- C1+'5D"(B K.7)&-,42.0,)$#$h L)/)*'0#/S-$0*'0)S4 Q)C"D"$5>7"/% ;"'&/1'#$b)8$1/1'#$)^#$1?#%15/-) ;"'&/1'#$b)))))))))))))))))) Q42.0,)$#$-#$-^)#/S-7'&#3'0)3-X-)/0)*#/S- 8$1/1'#$)))))))))))))))))))))) %&#/#%'&-7'&#3'0#./ ^#$1?#%15/ E^C)C"D"$5>7"/%N-:#.('*c)*-'$$'4-#/- %&#/#%'&-7'&#3'0#./ E^C)C"D"$5>7"/% =V
  18. 18. 35'&"g+)3"+"#('&)#/?)6#($B)C"D"$5>7"/%)R5?"$ Bringing the right disciplines together at the centre of drug discovery & early development ;(#/+$#%15/#$)R"?1'1/" JB+%"7).15$5<B !1<&"()_,#$1%B) !"#$%&'()*+)#',- 7-+)/#$3-+*1%&86)9'$: '$1/1'#$) '#/?1?#%"+ C1+'5D"(B)#/?);(#/+$#%15/#$)I("#+ E7>(5D"?) 89J C1+"#+" ^1(5$5<B F/'5$5<B R"%#@5$1') C1+"#+" E/0$#77#%15/ ,/?"(+%#/?1/<) 50)?1+"#+" ."%%"() R5?"$1/<)Q)J17,$#%15/ .157#(4"(+ '#/?1?#%") ./'0)*+)1'#'%-2&34'-, 5)6)03-$*$%%6# @157#(4"(+ =I
  19. 19. .157#(4"(+ Essential to enabling translational medicine and drug development [ f/?"(+%#/?1/<)>#%&:#B+)#/?)7"'&#/1+7+ )?S?-0'*S)0$@-(.&)%9&'*-()%,'/#$($-'/3-2'0,.2,4$#.&.S4]- [ E7>(5D"?)?"'1+15/)7#41/<)1/)3QC )?S?-0..&$-1.*-2*.1#&#/S-0'*S)0$@-%.(2.9/3$@-8"-'/3-$'1)04- A'*c)*$] [ C(1D"(+)05()>&#(7#'5?1#</5+%1')?"D"$5>7"/% )/,'/%#/S-*)$2./$)-*'0)$@-#(2*.7#/S-^)/)1#0X*#$c-*'0#.@- %.(2'/#./-3#'S/.$0#%$] =H
  20. 20. .157#(4"(+)#/?)*&#(7#'5?1#</5+%1'+ Biomarkers are essential tools in modern drug development and key to Personalised Healthcare Pharmacodiagnostic Biomarkers • Treatment eligibility • Response prediction • Safety and Efficacy Biomarkers perspective Pharmacological Disease Biomarkers Biomarkers • Pharmacodynamic • Patient risk markers • Early detection • Pharmacokinetic • Prognosis markers • Monitoring/ • Mechanism of action Recurrence markers !B
  21. 21. h,#$101'#%15/)50)/5D"$)@157#(4"(+ 8$1/1'#$)^#$1?1%B I/#$B%1'#$)^#$1?1%B [ R/3)*$0'/3-7'*#'^#&#04-#/-0,)-()'$9*#/S- [ R/3)*$0'/3-'/3-'%%.9/0-1.*-^#.&.S#%'&- $4$0)( 7'*#'^#&#04 [ D#(#0X%./0*.&-$.9*%)$-.1-7'*#'^#&#04 [ `/0)*2*)0-7'*#'^#&#04-#/-0,)-%./0)e0-.1- #/0)/3)3-9$) [ O&#/#%'&-90#&#04-)$0'^&#$,)3-^4-9$#/S-'- 7'&#3-^#.('*c)*-#/-0,)-%&#/#% +,)-GOOY 1*'()b.*c-G/'&40#%'&-7'&#3#04@-O&#/#%'&-7'&#3#04@ O&#/#%'&-90#&#04@-Y0,#%'&@-D)S'&-'/3->.%#'&-%./$#3)*'0#./$]@-#$-'22&#%'^&) 0.-1.*($-.1-(.&)%9&'*-3#'S/.$0#%$-'/3-^#.('*c)* ;&")1/%"/?"?),+")50)%&")@157#(4"()+&#>"+)7,'&)50)%&")?"D"$5>7"/%):5(4)#/?) /""?+)%5)@")?"'1?"?)#%)#/)"#($B)+%#<" !=
  22. 22. `&#%)#@5,%)7,$%1>$")7#(4"()>#/"$+a G33#0#./'&-%.(2&)e#04N [ Y'%,-()(^)*-.1-0,)-2'/)&-'33$-'/-'33#0#./'&-$.9*%)-.1- 2.0)/0#'&-)**.*-h0*'3)h.11$-#/-'33)3-$)/$#0#7#04-'0-2.0)/0#'&-%.$0- 0.-$2)%#1#%#04-(9$0-^)-('3) [ O./0*.&-1.*-#/0)*1)*)/%)-^)0b))/-)'%,-#/3#7#39'&-()(^)*-.1-0,)- 2'/)& [ `/%*)'$)3-%./$0*'#/0$-./ f >'(2&)-%.&&)%0#./@-2*)2'*'0#./-'/3-$0.*'S) f A)'$9*)()/0-$4$0)( f O./0*.&@-%'&#^*'0#./@-$0'/3'*3#E'0#./-%./%)20$ [ O.&&)%0#/S-3'0'-./-0,)-^#.('*c)*-2'/)&_$-2)*1.*('/%)-#/-0,)- #/0)/3)3-$)00#/S@-'22&#)3-0.-0,)-#/0)/3)3-%&#/#%'&-2.29&'0#./- !! )$$)/0#'&
  23. 23. .157#(4"()C1+'5D"(B)Q)C"D"$5>7"/% Analytical validation/quality needs differ according to intended use ;"'&/1'#$)b) .157#(4"()8#/?1?#%"+)C1+'5D"(B E^C)C"D"$5>7"/% 8$1/1'#$)D#$1?#%15/ 95[)50).157#(4"(+)#/?)I++#B+ h,#$1%B)("_,1("7"/%+)S'$1/1'#$)#/? #/#$B%1'#$)D#$1?1%B)50)#++#B+T !6
  24. 24. Z5',+)5/),/?"(+%#/?1/<)?1+"#+")#%)%&")75$"',$#()$"D"$ Increased effort to understand disease biology and translational medicine to achieve PHC "[<[))F/'5$5<B-) [ `")&#D")17>(5D"?)>(5'"++"+)05()>#%1"/%)+#7>$")'5$$"'%15/ f '()/3)3-`/1.*()3-O./$)/0@-('/3'0.*4-$'(2&)-%.&&)%0#./- $0*'0)S#)$ [ `")&#D")1/'("#+"?)5,()"005(%)1/)>("'$1/1'#$)>(501$1/< f #/%*)'$)3-3)20,-.1-2*)%&#/#%'&-2*.1#&#/S-./-%&9$0)*$-.1- (.&)%9&)$ )?S?-'/0#h'/S#.S)/)$#$]-#/%&93#/S-('*c)0)3-.*- &'0)-$0'S)-(.&)%9&)$ [ `")&#D")"=>#/?"?)5,()>#(%/"(+&1>+):1%&)#'#?"71') '577,/1%1"+ f +*'/$&'0#./'&-A)3#%#/)-Q9^-#/->#/S'2.*)-.2)*'0#./'&#E)3 #/- )'*&4-!B=B !;
  25. 25. 8$1/1'#$),%1$1%B)50)("+>5/+")>("?1'%15/ 5&'#$6#.$1,%+&-/ [ 5#$c$-'/3-^)/)1#0$-*)&'0)3-0.-jY(2#*#%-G22*.'%,_ f 2*)$9(20#7)-0*)'0()/0-7)*$9$-0)$0-'/3-0*)'0 f /'09*)-.1-#&&/)$$-'%90)@-&#1)h0,*)'0)/#/S]-'/3-0*)'0()/0-'&0)*/'0#7)$ [ +,)*'2)90#%-*)$2./$)-*'0) f 5)&'0#7)&4-,#S,-kJBU]-.*-&.b-l-6BU]? [ 5)&'0#7)-%.$0$ f 0.0'&-%.$0-.1-'%a9#*#/S-0)$0-#/1.*('0#./-0#()-'/3-(./)4]-7)*$9$ $'7#/S$-1*.(- 0)$0#/S f 2)*%)#7)3-'33#0#./'&-7'&9)-39)-0.-*)39%0#./-.1-2'0#)/0-9/%)*0'#/04 [ 5)&'0#7)-2*)3#%0#7)-7'&9) f ,.b-b)&&-3.)$-0,)-0)$0-#/1.*(-%&#/#%'&-3)%#$#./-('c#/Sd [ `$$9)$-*)&'0)3-0.-('*c)0-'%%)20'/%)X2*'%0#%'&#04 f 0)$0-2&'01.*(-'7'#&'^#&#04@-2,4$#%#'/-)39%'0#./-'/3-'%%)20'/%)-)0%? !<
  26. 26. J57"%17"+)+%#(%1/<)>51/%)05()("+>5/+")7#(4"(+)5@D15,+[[ MDM2 Biomarker Program • MDM2 is the master regulator of p53 • Antagonists of p53-MDM2 binding can activate the p53 pathway and restore cell cycle MDM2 inh binds to MDM2 min the p53 binding arrest and apoptosis pocket [ A"A! '/0'S./#$0$-b#&&-&#c)&4-/.0-^)-^)/)1#%#'&-1.*-2'0#)/0$-b#0,-09(.*$-(90'0)3-1.*-2<6 '22*.e-<B-U-.1-,9('/-09(.*$] [ 8'0#)/0-$0*'0#1#%'0#./-^4-2<6-S)/)-$0'09$-*)a9#*)3-0.-#3)/0#14-2.0)/0#'&-*)$2./3)*$ Roche Diagnostics developing a test platform for p53 resequencing p53 AmpliChip !J Roche RMD
  27. 27. ;#(<"%1/<).3IZ R,%#%15/+)1/)8#/'"( One promising early phase example [ ;5<= <"/")7,%#%15/+)?"%"'%"?)1/)iVH)50)#$$) '#/'"(+ f R2-0.-VBU-.1-('&#S/'/0-()&'/.('$ f R2-0.-<6U-.1-2'2#&&'*4-0,4*.#3-%'*%#/.('$ f R2-0.-=<U-.1-%.&.*)%0'&-09(.*$ [ R5+%)'5775/)7,%#%15/)@B)0#(-)^PMM6)1/)"=5/)KL f n-VBU-()&'/.('$@-0,4*.#3-'/3-%.&.*)%0'&-%'/%)*$-- b#0,-(90'0)3-=>?@ 5GW-'%0#7'0)$-0,)-AG8M-$#S/'&#/S-2'0,b'4 :5GW-%'/-^)-'%0#7'0)3-^4-'-$#/S&)-(90'0#./-gJBBY] *eOMXN N-K.7)&-$('&&h(.&)%9&)- #/,#^#0.*-1*.(-8&)ee#c./ 85C=)/""?N-+'a('/o 8O5h^'$)3- 8)94%#):#!"4)!6NJVV=-!BB<]-A-:))*'( (&),4;<)9,#!(.)9(44)JN6=6-!BB;]-AF-L'*/)00-'/3-5-A'*'#$- gJBBY (90'0#./-3)0)%0#./ !V
  28. 28. C"01/1/<)("+>5/+")1/)>#%1"/%+):1%&)3&",7#%51?)I(%&(1%1+ 3"+>5/+")7"#+,("?)@B)'57>5+1%")+'5("+ f I83)S17>(5D"7"/%)/5%)#'%1D1%BT [ GO5!B-f '-!BU-#(2*.7)()/0-#/-+FO-'/3->FO-'/3-#/-6-.1-0,)-1.&&.b#/S- f 8'0#)/0-S&.^'&-'$$)$$()/0 f 8,4$#%#'/$-S&.^'&-'$$)$$()/0 f 8'0#)/0$-'$$)$$()/0-.1-2'#/ f ")S*))-.1-3#$'^#&#04- f D)7)&-.1-'%90)-2,'$)-*)'%0'/0$ f CIJ)S17>(5D"7"/%)#/?)#'%1D1%BT [ `/%&93)$-'*0#%9&'*-#/3)e@->FO@-Y>5@-8'0#)/0-S&.^'&-'$$)$$()/0 f L..3-*)$2./$)-"G>-l!?;C-"k=?! f K./h*)$2./3)*-"G>-k6?VC-"lB?J f C100"("/%)%&"(#>1"+)7#B)>(5?,'")?100"("/%)"00"'%+)5/)%&")'57>5/"/%+)50)#) '57>5+1%")+'5(")j #/?)%&"("05(")5/)%&")7"#+,("7"/%)50)("+>5/+" !I
  29. 29. C1+'5D"(1/<)#/?)1/%"<(#%1/<)/5D"$)("+>5/+") 7#(4"(+)1/%5)?(,<)?"D"$5>7"/% O,'&&)/S)$m [ O.**)&'0#./-.1-/.7)&-('*c)*$-b#0,-*)$2./$)-*)a9#*)$-0,'0-0,)*)-^)-$911#%#)/0- *)$2./3)*$-#/-)'*&4-3)7)&.2()/0 [ ".-b)-,'7)-0,)-*#S,0-*)$2./$)-2,)/.042)d-)?S?-09(.*-*)$2./$)-7)*$9$- $9*7#7'& [ ".)$-0,)-('*c)*-3)1#/)-*)$2./$)-2*)3#%0#7)]-.*-'-3#11)*)/0-%.9*$)-.1-3#$)'$)- 2*.S/.$0#%]-.*-^.0,d [ Q'7)-b)-S.0-'%%)$$-0.-0,)-*#S,0-042)-.1-%&#/#%'&-$'(2&)$d-'/3-,'7)-0,)4- ^))/-$0.*)3-%.**)%0&4m?] [ Q42.0,)$#$-1*))-'22*.'%,)$-)?S?-ZLG>@-0*'/$%*#20.(#%$]-()'/-0,'0-b)-3./_0- ,'7)-0.-$0'*0-b#0,-'-,42.0,)$#$@-^90-b#&&-&)'3-0.-('/4-1'&$)-p7)_$ [ A'4-.10)/-*)$9&0-#/-$0*'0#1#%'0#./-,42.0,)$)$-^)#/S-3)7)&.2)3-2.$0-#/#0#'&- &#%)/$#/S-.1-(.&)%9&)m? !H
  30. 30. E/%"/?"?),+")50)@157#(4"()?"%"(71/"+)("_,1("?) >"(05(7#/'" !-,0#$&11/$7*$/#*/7+747+.$4#-/2/$/(#%717%7+. Serious illness: don’t withhold therapy inappropriately + response - response + test true positive & false positive - test ' false negative true negative Efficacy marker: High sensitivity + adverse event - adverse event + test true positive ' false positive - test & false negative true negative Safety marker: High specificity Less serious illness: don’t prescribe inappropriately + response - response + test true positive ' false positive - test & false negative true negative Efficacy marker: High specificity + adverse event - adverse event + test true positive & false positive - test ' false negative true negative Safety marker: High sensitivity 6B
  31. 31. *&#(7#'5?1#</5+%1')%"+%)("_,1("7"/%+ [ 3"$1#@$")%"+%+ f &.b-7'*#'^#&#04-h *.^9$0-'/3-*)2*.39%#^&) f ,#S,&4-2*)3#%0#7) [ 6#+B)%5)#?71/1+%"( f b,.&)-^&..3X$)*9(-h ^#.2$4d f *'2#3-0)$0-09*/'*.9/3 f 7'&9)-.1-0)$0-#/1.*('0#./-.90b)#S,$-'%a9#$#0#./-%.$0$-0#()X%.$0X#/7'$#7)/)$$] [ `1?"$B)#D#1$#@$" f '7'#&'^#&#04-.1-0)$0-/.-,#/3*'/%)-0.-('*c)0#/S-.1-3*9S f 0)$0#/S-2&'01.*(-b#0,-('/4-2&'%)()/0$-.*-&.b-'%a9#$#0#./-%.$0$ [ 85/',(("/% f '22*.7'&-.1-0)$0-%./%9**)/0-b#0,-3*9S-'22*.7'& 6=
  32. 32. 3"_,1("7"/%+)50)#)*&#(7#'5?1#</5+%1')>#(%/"( [ `/0)*/'0#./'&-2*)$)/%) f b#3)-%.(()*%#'&-*)'%, f *)S9&'0.*4-/)0b.*c-1.*-W"GXOYXF'2'/X>"G [ G%%)$$-0.-^*.'3-*'/S)-.1-0)%,/.&.S#)$ f )e2)*#)/%)-b#0,-*)a9#*)3-0)$0#/S-2&'01.*( f `8-^'**#)*$-/.-2*.^&)(-f 1*))3.(-0.-.2)*'0) [ D'*S)-#/$0'&&)3-^'$)-.1-$4$0)($ [ L..3-0*'%c-*)%.*3-#/-3)7)&.2()/0X*)S9&'0.*4-'11'#*$ [ K.-#$$9)$-b#0,-%.(2)0#0#7)-2*.39%0$X*)&'0#./$,#2$ 6!
  33. 33. +,)-2)*$2)%0#7)-.1-0,)-"#'S/.$0#%$-:9$#/)$$ 66
  34. 34. J5,('"+)50)95D"$)E^C)R#(4"(+)#/?)I$<5(1%&7+ Mix of internal programs, collaborative programs and in- licensing E/2$1'"/+1/<)0(57) E/2&5,+")7#(4"() #'#?"71#G)@15%"'&)5() ?1+'5D"(B)>(5<(#7+ 5%&"()?1#</5+%1') '57>#/1"+ 85$$#@5(#%1D") 35'&")*&#(7# >(5<(#7+):1%&) @157#(4"()>(5<(#7+ X(? >#(%B)*&#(7# #'#?"71#)#/?)@15%"'& '57>#/15/)?1#</5+%1'+ 6;
  35. 35. e#(<")*5(%05$15)50);"+%1/<)*$#%05(7+ Maintenance of existing test portfolio requires considerable investment '5@#+k IBBB- '/'&4E)*-$)*#)$ '5@#+k JBBB- '/'&4E)*-$)*#)$ '5@#+k ;BBB- '/'&4E)*-$)*#)$ JB+%"7)*5(%05$15)1/)%&")J"(,7)`5(4)I("#)50)35'&")*(50"++15/#$)C1#</5+%1'+ 6<
  36. 36. 95D"$)E^C)#++#B+)4"B)05()%&")E^C)E/?,+%(B Testing Efficiency and Medical Value key drivers of innovation & growth E/+%(,7"/% E//5D#%15/ ;"+%1/< 6001'1"/'B R"/, .("#?%& `5(40$5: Q)E; C"D"$5> 9": 85/%"/% R"?1'#$ ^#$," I>>$B 85/%"/%)05( 9":)f+"+ C"'"/%(#$1]" ;"+%1/< 6J
  37. 37. R"?1'#$)^#$," Finding & driving new content addressing high medical needs C"D"$5> Z5',+)5/-) >)+'136*?36") 9": [ &)7)&-.1-9/()0-()3#%'&- 85/%"/% /))3 I>>$B [ 3#$)'$)-^#.&.S4- 85/%"/%)05( 9/3)*$0'/3#/S 9":)f+"+ [ ,)'&0,h)%./.(#%-7'&9) d :&#%)1%)%#4"+ =? ")7)&.2()/0-i-#(2&)()/0'0#./-.1-%*.$$h:G-3#$)'$)h'*)'-$0*'0)S#)$ !? `(2&)()/0'0#./-.1-'-$4$0)('0#%-2*.%)$$-0.-)11#%#)/0&4-'%%)$$-/)b %./0)/0 [ `3)/0#1#%'0#./-i-1#/3#/S@-'%%)$$#/S-i-$)%9*#/S-"e-`8XW+P@-3)7)&.2#/S- '$$'4$@-1'$0-i-#/1.*()3-3)%#$#./h('c#/S 6V
  38. 38. I''"++)R"?1#$)^#$,").157#(4"(+)05()F/'5$5<B Two key focus areas & approaches C1#</5+%1'+ [ >%*))/#/S [ "#'S/.$#$ ;("#%7"/%) [ 8*.S/.$#$ [ 8*)3#%0#./ R#>+ >)+'136*?36") [ A./#0.*#/S 857>#/15/ C1#</5+%1'+ [ +*)'0()/0-$)&)%0#./ R5$"',$#() l [ 5)$2./$)-2*)3#%0#./ *#%&:#B+ 6I
  39. 39. F>>5(%,/1%B)#++"++7"/% Unmet needs in many areas of patient management Q)'&0,4 G$4(20.('0#%- >4(20.('0#%-3#$)'$) O,*./#%-3#$)'$)- 3#$)'$) O9*)3 31+4) J'(""/1/<b) I++"++7"/% C1#</5+1+ *(5</5+%1' *("?1'%1D" R5/1%5(1/< 8*)3#$2.$#0#./- 8*)3#%0- 8*)3#%0-&#c)&4- A./#0.*- Y'*&4- 1.*-3)7)&.2#/S- 2*.^'^&)- *)$2./$)-0.-'- )11#%'%4X- 3)0)%0#./ 3#$)'$) 3#$)'$)-%.9*$) 3*9S *)%9**)/%) 8'0#)/0->0*'0#1#%'0#./-X-+,)*'24->)&)%0#./ +,)*'24-'3'20'0#./ 6H
  40. 40. J%(#%"<1')*(15(1%1]#%15/)50)Z5',+)E/?1'#%15/+ 8,9&-$:-7+#-7,$ [ A'#/-1.%9$-#$-./-'*)'$-0,'0-'*)-('q.*-%./0*#^90.*$-0.-(.*^#3#04-'/3- (.*0'&#04-#/-3)7)&.2)3-%.9/0*#)$ $9%,-'$-O'*3#.7'$%9&'*-"#$)'$)$@- A)0'^.&#%-"#$.*3)*$-)?S?-"#'^)0)$-i-K)2,*.2'0,4@-P/%.&.S4@- P$0).3)S)/)*'0#7) "#$.*3)*$-'/3-OK>-3#$)'$) [ G*)'$-b,)*)-#/h7#0*.-&'^.*'0.*4-0)$0$-$)*9(-'$-$'(2&)-.1-%,.#%)]- '*)-%./$#3)*)3-0.-^)-('q.*-3#'S/.$0#%-%./0*#^90.*$ [ G%0#./'^#&#04 .1-0,)-0)$0-*)$9&0-b#&&-#0-&)'3-0.-'-%,'/S)-#/-2'0#)/0-- %'*)] [ >0*'0)S#%-1#0-0.-)e#$0#/S-0)$0-()/9 ;B
  41. 41. R#c5()h,"+%15/+)05()9":)R#(4"())))))))))))))))))))) #/?)I$<5(1%&7)C"'1+15/+) K[ `$-0,)-('*c)*X'&S.*#0,(-'$1/1'#$$B),+"0,$d-`/0)/3)3-9$)-b.*c#/S- ,42.0,)$#$-'/3-'7'#&'^&)-)7#3)/%)-)e#$0#/S-3'0'-.*-3'0'-0.-^)-S)/)*'0)3- 0.S)0,)*-b#0,-$%#)/0#1#%-%.&&'^.*'0#./$]@-#/%&93#/S-'$$)$$()/0-.1- %.(2)0#0#7)-3#'S/.$0#%-0)%,/.&.S#)$ N[ ".)$-0,)-7#(4"% +1]" q9$0#14-0,)-#/7)$0()/0-.*-2*.7#3)-%.(2)0#0#7)- '37'/0'S)-#1-2*.39%0-3)7)&.2()/0-%'/-/.0-^)-q9$0#1#)3-'$-$0'/3h'&./)d X[ G*)-0,)-0)$0$-%"'&/1'#$$B 0"#+1@$" ./-5.%,)-2&'01.*($d O[ `$-0,)-0)%,/.&.S4-%.7)*)3-^4->#%"/%S+Td L[ `$-0,)*)-#''"++)%5)#)$1'"/+" '/3-'0-b,'0-%.$0$d P[ Q.b-^#S-'*)-0,)-*)a9#*)3-"005(%+)05()7#(4"%)?"D"$5>7"/%d %&#/#%'&-3)7)&.2()/0@-*)S9&'0.*4-'22*.7'&-'/3-('*c)0-3)7)&.2()/0-%.$0$] ;=
  42. 42. 9":)R#(4"()J"#('&)Z5',+)05()*(5%"1/)#/?) R"%#@5$1').157#(4"(+ FD#(B *(5+%#%" *"$D1')R#++ F/'5$5<B J%(54" *,$75/#(B S;(#,7#T !88 C1+"#+"+ ^#+',$#() 3"75?"$$1/< e1D"( C1+"#+"+ e1D"(2 Z1@(5+1+ 9">&(5>#%&B 9IJ!b9IZeC 8#(?15$5<B 81((&5+1+ I%&"(5+'$"(5+1+ R"%#@5$1')JB/?(57" 9"'(5+1+ C1#@"%"+ E/0[)C1+[ J">+1+ ;!
  43. 43. J'5>1/<)50)8#(?15^#+',$#( C1+"#+" 8*.S*)$$#./-.1-G0,)*.$%&)*.$#$ $)%./3'*4 %.(2&#%'0#./$@- K.-$4(20.($- >4(20.($-.1- >4(20.($-.1-G%90)- K.-2)*%)20#^&)- K.-$4(20.($- >4(20.($-.1- >4(20.($-.1-G%90)- K.-2)*%)20#^&)- 3#$)'$)- C1+"#+") .1-3#$)'$)@- O,*./#%-3#$)'$)- 3#$)'$)- 8.$0h'%90)@-/))3-1.*- )7#3)/%)- .1-3#$)'$)@- O,*./#%-3#$)'$)- 8.$0h'%90)@-/))3-1.*- )7#3)/%)- O,)$0-8'#/@->.:@- +%#<"+ 3#$2&'4-.1-*#$c-1'%0.*$- $0'^&)-'/S#/'@- O,)$0-8'#/@->.:@- $9*7)#&&'/%)X1.&&.b-92 .1-3#$)'$) 3#$2&'4-.1-*#$c-1'%0.*$- $0'^&)-'/S#/'@- >0*.c)@-G%90)-D#(^- $9*7)#&&'/%)X1.&&.b-92 .1-3#$)'$) >0*.c)@-G%90)-D#(^- $0'S)-G] $,.*0/)$$-.1-^*)'0,] "#$%.(1.*0-OD`]] $0'S)-G] $,.*0/)$$-.1-^*)'0,] "#$%.(1.*0-OD`]] ;&")/""?)05() >("D"/%15/G)75?10B1/<) %&"(#>B >("?1+>5+1%15/ ?1#</5+1+ 75/1%5(1/< %"+%1/< 50)(1+4)0#'%5(+ +%(#%101'#%15/ 85/+,7"()l) >&B+1'1#/a C5'%5(g+) *#%1"/%) C5'%5(g+)5001'" 5001'" +"%%1/< !5+>1%#$)6Cb88bE8f I7@,$#%5(Bb) C#B'#(" ;6
  44. 44. .157#(4"()C"D"$5>7"/%)j 3"_,1("?)8#>#@1$1%1"+ Significant challenges to establishing clinically viable and useful biomarkers 8577"('1#$1]#%15/ O&#/#%#'/X-D'^-)39%'0#./ G93#0#/S-1.*-*)$9&0-%./$#$0)/%4 "#$0*#^90#./-0.-&'^.*'0.*#)$ ^#$1?#%15/b h,#$101'#%15/ 5)S9&'0.*4-0)$0-'22*.7'& G$$'4-*)1#/)()/0-i-3)7)&.2()/0-`g"-0)$0 O&#/#%'&-7'&#3'0#./-.1-%'/3#3'0)-('*c)*$-9$#/S-'$$'4 C1+'5D"(B ")7)&.2-2*.0.042)-'$$'4 `3)/0#1#%'0#./-.1-%'/3#3'0)-('*c)*$ L)/)*'0#./-.1-'-^#.('*c)*-,42.0,)$#$ ;;
  45. 45. 35'&")C1#</5+%1'+) ;#/73*$:&*+-&)$,*0$:&''#-%7,)7<,+7&*$5+,*0,-0 Analysis Feasibility Development Implementation Manufacturing Sales C"+1</ C"+1</ C"+1</ e#,/'& 8.$0 >0'*0 D'9/%, D'9/%, m5#$+ E/>,% F,%>,% C"'1+15/ 5)7#)b ")$#S/-S.'&$@-2*.39%0-7#$#./ W)'$#^#&#04-'22*.7)3 W9/%0#./'&-(.3)&-")7)&.2()/0- 5)2*.39%#^#&#04-2*.7)/ A'*c)0-$#09'0#./-'$$)$$)3 A'*c)0-'/3-%9$0.()*-*)a9#*)()/0$- *)1?-&.0-'22*.7)3- >%'&)h92-%.(2&)0)3@-2*.%)$$)$- +)%,/#%'&-*)'&#E'0#./-'$$)$$)3 '/'&4E)3 3)$#S/X2)*1.*('/%)] 1#/'&#E)3-'/3-7'&#3'0)3 `/#0#'&-2*.q)%0-2&'/ :9$#/)$$-*)a9#*)()/0$- 8*.0.042)XA'$0)*-2#&.0-&.0- 8*.39%0#./-&.0-3)1#/)3 `/#0#'&-2*.1#0'^#&#04-%,)%c %./$#3)*)3 '22*.7)3 3)$#S/-'/3- 8)*1.*('/%)-7)*#1#%'0#./-'/3 +)%,/#%'&-1)'$#^#&#04-3)(./$0*'0)3 2)*1.*('/%)] )e0)*/'&-7'&#3'0#./-%.(2&)0)3 8*.39%0-'/3-2*.q)%0-*#$c-'$$)$$)3 >2)%#1#%'0#./$-%./1#*()3-#1- A'*c)0#/S-2*)2'*)3 D)S'&-'/3-*)S9&'0.*4-#$$9)$ /))3)3-^4-%9$0.()*$] ")7#%)-('$0)*-*)%.*3 %./$#3)*)3 5p"-3)7#%)-('$0)*-*)%.*3- O)*0#1#%'0#./-('*c$-S*'/0)3 K)S.0#'0)3-$2)%#1#%'0#./$ 2*.39%0-3)1#/)3@-3)1#/)3- 5)S9&'0.*4-1#&)$-./-2&'/ ")0'#&)3-2*.q)%0-2&'/ ('0)*#'&$@-$922&4--%,'#/-'/3- 8'0)/0-'/3-&#%)/$#/S-#$$9)$- 8*.1#0'^#&#04-'$$)$$)3 &.S#$0#%$-%./%)20-)$0'^&#$,)3- %&)'*)3 2*.%)39*)$--'/3-*.^9$0/)$$ W#/'&-2*.39%0-*#$c-$0'0)()/0 )$0'^&#$,)3 D'9/%,-'%0#7#0#)$-2&'//)3-#/-3)0'#& 8*.q)%0-2&'/-923'0) 8*.1#0'^#&#04-%./1#*()3 8*.1#0'^#&#04-923'0) ;&1+)1+) ;&1+)1+):&#%):")/""?[ ;&1+)1+):&#%):"):#/%)%5 ;&")?"D"$5>7"/%)1+) `")'#/)7#4")1%[)`")#(") `")+"$$)%&") e"++5/+) >(571+1/<[ 7#4"[);&")@"+%)'5/'">% 01/1+&"?[)J>"'101'#%15/+ ("#?B)%5)+"$$[ >(5?,'%[ $"#(/%[ Z1/?)5,%) &#+)@""/)1?"/%101"?)#/? &#D")@""/)7"%[ 75(" #/?)<"%)@#'4 1%)1+)0"#+1@$"[ %5),+[ ;<
  46. 46. C1#</5+%1'+)J,77#(B [ +,)-3)7)&.2()/0-.1-/.7)&-`g"-0)$0$-#$-'/-#(2.*0'/0-S*.b0,-'/3-#//.7'0#./- 3*#7)*-1.*-0,)-`g"-#/39$0*4 [ +,)-2*.%)$$-1.*-3)7)&.2()/0-.1-/.7)&-`g"-0)$0$-#$-%.(2&)e-'/3-*#$c4-'/3- *)a9#*)$-0,)-#/39$0*4-0.-#/0)*1'%)-b#0,-$0'c),.&3)*$-#/-'%'3)(#'@-0,)- 8,'*('-#/39$0*4-'/3-%.(2'/#)$-1.%9$$)3-./-^#.('*c)*-3#$%.7)*4-'/3- 3)7)&.2()/0?-O.&&'^.*'0#./-b#0,-.0,)*-#/39$0*4-$0'c),.&3)*$-#$-)$$)/0#'&-0.- 0,)-`g"-#/39$0*4 [ A'#/0'#/#/S-0,)-%9**)/0-0)$0-2.*01.&#.-./-)e#$0#/S-$4$0)($-'/3-3)7)&.2#/S- '22&#%'0#./$-1.*-0,)$)-0)$0$-./-/)b-'/3-*)2&'%)()/0-$4$0)($-*)a9#*)$- $#S/#1#%'/0-#/7)$0()/0@-&#(#0#/S-0,)-19/3$-'7'#&'^&)-1.*-#/7)$0()/0-#/-/.7)&- 0)$0$ [ O.(2'/#./-3#'S/.$0#%-0)$0$-'/3-0)$0$-^'$)3-./-^#.('*c)*$-9$)3-#/ 8,'*('- 3#$%.7)*4-'/3-%&#/#%'&-3)7)&.2()/0-2*.S*'($-b#&&-%./0*#^90)-$#S/#1#%'/0&4-0.- 0,)-2#2)&#/)-.1-/.7)&-`g"-0)$0$-#/-%.(#/S-4)'*$ [ 5.%,)-"#'S/.$0#%$-#$-%.((#00)3-0.-#//.7'0#./-0,*.9S,-0,)-()3#%'& 7'&9)- 2*.7#3)3-^4-/.7)&-`g"-0)$0$-'/3-b.*c$-%&.$)&4-b#0,-'-b#3)-*'/S)-.1-2'*0/)*$- ;J 0.-'%,#)7)-0,#$
  47. 47. 35'&")m(5,> Differentiation through Personalised Healthcare [ +,)*)-'*)-$0#&&-('/4-%,'&&)/S)$-0.-.7)*%.()-#/-^#.('*c)*- 3#$%.7)*4@-7'&#3'0#./-'/3-%.(()*%#'&#E'0#./- [ `/-$2#0)-.1-0,)$)-%,'&&)/S)$@-5.%,)-#$-%.((#00)3-0.- 8)*$./'&#$)3 Q)'&0,%'*)-f ^)%'9$)-#0_$-c)4-0.-.9*-(#$$#./-.1- 3)7)&.2#/S-#//.7'0#7)-()3#%#/)$-'/3-3#'S/.$0#%$-1.*-0,)- ^)/)1#0-.1-2'0#)/0$-'/3-$.%#)04 [ "#'S/.$0#%$-%'2'^#&#0#)$-'/3-0)%,/.&.S#)$-2&'4-'-%*9%#'&-*.&)-#/ 3#$%.7)*#/S-i-,'*7)$0#/S-^#.('*c)*$ [ Q'7#/S-"#'S/.$0#%$_ %'2'^#&#0#)$-#/0)*0b#/)3-0,*.9S,.90-'&&- $0'S)$-.1-3*9S-3)7)&.2()/0-#$-'-$#S/#1#%'/0-'37'/0'S) ;V
  48. 48. =#$>**&4,+#$?#,)+"%,-# ;I

×